

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL676224322US

Date of Deposit: March 29, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Tamara Venegas
Tamara Venegas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas INNERARITY and Jan BOREN

Serial No.: To Be Assigned

Filing Date: Herewith

For: METHODS AND TOOLS FOR
IDENTIFYING COMPOUNDS WHICH
MODULATE ATHEROSCLEROSIS BY
IMPACTING LDL-PROTEOGLYCAN
BINDING

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

PRELIMINARY AMENDMENT

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The above-referenced application is a divisional under 37 C.F.R. § 1.53(b) of Application No. 09/265,222. Prior to examination on the merits, applicants respectfully request that the following amendments be entered and considered.

In the Specification

On page 1, under the title, please insert the following new paragraph:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of application Serial. No. 09/265,222, filed March 5, 1999, which claims priority under 35 USC § 119(e) to U.S. Provisional Application Serial No. 60/077,618, filed March 10, 1998, the entire contents of which are incorporated herein by reference.

In the claims

Please cancel claims 1-22 and 24-28 without prejudice or disclaimer.

Please amend claim 23 as follows:

23. (Once Amended) A polynucleotide encoding an apo-B100 protein comprising a proteoglycan receptor⁺ mutation in Site B.

REMARKS

Following entry of this preliminary amendment, claim 23 will be pending in the present application. Claim 23 has been rewritten to eliminate reference to cancelled dependent claims 15-18, and to recite “an apo-B100 protein comprising a proteoglycan receptor⁺ mutation in Site B” (rather than “an apo-B100 protein according to claim 14”). Support for the amendment is found in original claims 14 and 23. No new matter has been added.

Attached hereto is a marked up version of the changes made to the claims and the specification by the current amendment with additions underlined and deletions bracketed. The attached page is captioned “**VERSION WITH MARKINGS TO SHOW CHANGES MADE**”.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing

docket no. 220002059711. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: March 29, 2001

By: Cara Coburn
Cara Coburn
Registration No. 46,631

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-4218
Facsimile: (650) 494-0792

VERSION WITH MARKINGS TO SHOW CHANGES MADE

U.S. Serial No. To Be Assigned
Attorney Docket No. 220002059711

In the specification

On page 1, under the title, a new paragraph has been added.

In the claims

23. (Once Amended) A polynucleotide encoding an apo-B100 protein [according to any one of claims 14 to 18] comprising a proteoglycan receptor⁺ mutation in Site B.